Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Public Citizen’s Health Group Changes Leadership, But Wolfe Remains On Prowl

Executive Summary

Wolfe steps down to become senior advisor but remains a vocal critic of the pharmaceutical industry and FDA, as his appearance at the Avandia advisory committee meeting demonstrated.

You may also be interested in...



Avandia Committee Gives Split Vote To Drug, But FDA Clear Winner

A re-adjudication of cardiovascular events in the RECORD trial reassured members of a June 5-6 advisory committee that the study findings are reliable, but did not erase uncertainties about CV risk associated with rosiglitazone.

FDA Intellectual Bias Policy Takes Wolfe Off Contraceptives Safety Review

FDA offered Public Citizen’s Sidney Wolfe a seat at the table for discussion, but no vote. Members need to report relevant information about their conflicts in a timely manner, the agency says.

Cardiac Risks Of Propoxyphene Raced Out Of Control As FDA Moved For Immediate Withdrawal

In deciding that the pain drug propoxyphene should come off the market, Center for Drug Evaluation and Research officials went from believing there was insufficient evidence of cardiac harm at therapeutic doses to concluding there was no way the risks of heart arrhythmia could be managed and mitigated.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS055410

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel